Ethnicity Breakdown
The majority of participants were white (97%), followed by 0.7% African-American.
Diagnosis & Evaluation Methods
For a detailed description, see ADAPT Research Group, et al. 2009.
References
Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN,ADAPT Research Group. Extended results of the Alzheimer's disease anti-inflammatory prevention trial.Alzheimers Dement. 2011 Jul;7(4):402-11.
ADAPT Research Group, Meinert CL, McCaffrey LD, Breitner JC .Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement. 2009 Mar;5(2):93-104.
ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008 Jul;65(7):896-905. Epub 2008 May 12.
ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007 May 22;68(21):1800-8. Epub 2007 Apr 25.